Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 125
interventional 100
Observational 24
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Biological|placebo 32
Drug|placebo 27
Biological 18
Drug 16
Drug|Other 2
Behavioral 1
Biological|placebo|Procedure 1
Diagnostic Test 1
Other 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 38
United Kingdom 18
Japan 4
Australia 2
Belgium 2
NA 2
Argentina|Bangladesh|Brazil|Colombia|Malaysia|Mexico|Panama|Philippines|South Africa|Thailand 1
Argentina|Chile 1
Australia|Belgium|Bulgaria|Estonia|Hungary|Israel|Latvia|Malaysia|Philippines|Poland|Slovakia|Spain|Thailand|United Kingdom 1
Australia|Chile|New Zealand 1
Australia|Hong Kong|Israel|Lebanon|Malaysia|Poland|Taiwan|Turkey 1
Belgium|Estonia|France|Germany 1
Canada 1
China 1
France 1
Germany 1
Germany|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Czechia|Estonia|Finland|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|New Zealand|Panama|Poland|Russian Federation|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
Netherlands 1
Poland|United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|France|Germany|Japan|Korea, Republic of|Mexico|Russian Federation|South Africa|Spain|Sweden|Taiwan|Ukraine 1
Poland|United States|Brazil|Canada|Colombia|Finland|Italy|Mexico|Panama|Spain|Thailand|Turkey|United Kingdom 1
Russian Federation 1
Spain|Israel|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Czechia|Estonia|Finland|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|New Zealand|Panama|Poland|Russian Federation|South Africa|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Chile|Czech Republic|Denmark|France|Germany|Greece|Hungary|Iceland|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom 1
United States|Argentina|Australia|Bangladesh|Chile|Mexico|New Zealand|Philippines|South Africa|Spain|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Estonia|Finland|France|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|South Africa|Spain|Sweden|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|France|Germany|Israel|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Russian Federation|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Canada|France|Germany 1
United States|Australia|Belgium|France|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|United Kingdom 1
United States|Australia|Bulgaria|Canada|Chile|Denmark|Finland|Germany|Hungary|Netherlands|New Zealand|Panama|Puerto Rico|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|Chile|Colombia|France|Japan|New Zealand|Panama|Romania|South Africa|Taiwan|Thailand|United Kingdom 1
United States|Australia|Canada|Finland|France|New Zealand|Panama|South Africa|Spain 1
United States|Australia|Czechia|Germany 1
United States|Australia|New Zealand|Singapore|Taiwan 1
United States|Belgium 1
United States|Belgium|Canada 1
United States|Brazil 1
United States|Canada|Italy|Mexico|Panama|Poland|Spain|Taiwan 1
United States|Finland|Germany 1
United States|France|Korea, Republic of|Sweden|Switzerland 1

Sites per Study

Site_count Study_Count
1 52
2 3
3 5
4 1
5 1
6 1
7 2
8 3
10 2
11 1
12 3
13 1
17 2
19 2
21 2
22 1
24 1
28 1
30 1
33 1
36 1
37 1
39 1
43 1
59 1
77 1
88 1
124 1
145 1
161 1
205 1
277 1
344 1
351 1

Phase

Phase Study_Count
Phase 1 49
Phase 2 31
N/A 8
Phase 3 6
Phase 1/Phase 2 3
Phase 2/Phase 3 2
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 9
2 45
3 14
4 10
5 4
6 4
7 3
8 3
9 1
10 1
14 1
15 1
NA 4

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 24.00 3.00000 53.0000 7.0000 100 28.000 120
1st Qu. 38.25 30.00000 54.5000 63.0000 450 372.250 120
Median 83.50 48.00000 56.0000 88.0000 800 2088.500 120
Mean 642.00 91.93878 108.6667 222.2258 800 2596.667 120
3rd Qu. 128.00 80.00000 136.5000 317.5000 1150 4227.000 120
Max. 4600.00 1055.00000 217.0000 1453.0000 1500 6635.000 120

Trial Group Type

group_type Group_Count
Experimental 205
Placebo Comparator 80
Active Comparator 17
Other 14
NA 4
No Intervention 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 83
Single Group Assignment 15
Sequential Assignment 1
NA 1

Primary Purpose

primary_purpose Study_Count
Prevention 45
Treatment 40
Basic Science 7
Other 4
Diagnostic 1
Screening 1
Supportive Care 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 9
United Kingdom 4
NA 2
Argentina|Chile|Colombia|Ecuador|Mexico|Peru|Uruguay 1
Austria|Belgium|France|Germany|Italy|Norway|Poland|Slovenia|Spain|United Kingdom 1
Belgium|Netherlands|United Kingdom 1
Brazil 1
Canada 1
Finland|Netherlands|Spain|United Kingdom 1
Peru 1
Sweden 1
Turkey 1

Sites per Study

Site_count Study_Count
1 13
2 2
3 2
4 1
5 2
15 1
24 1
37 1
59 1

Enrollment Metrics

Measure Observational
Min 29.00
1st Qu 115.00
Median 305.00
Mean 34721.38
3rd Qu 1280.00
Max 787000.00

Observation Model

observational_model Study_Count
Cohort 13
Case-Only 4
Case Control 2
NA 2
Defined Population, Natural History 1
Ecologic or Community 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 18
Cross-Sectional 3
Retrospective 2
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
NA 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 30804
1st Qu 30804
Median 30804
Mean 30804
3rd Qu 30804
Max 30804

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
10 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03382431 A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study https://ClinicalTrials.gov/show/NCT03382431 Completed Pulmocide Ltd 2018-05-09
NCT03379675 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT03379675 Completed Janssen Research & Development, LLC 2019-11-27
NCT03334695 An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults https://ClinicalTrials.gov/show/NCT03334695 Completed Janssen Vaccines & Prevention B.V. 2018-07-10
NCT03332459 A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection https://ClinicalTrials.gov/show/NCT03332459 Completed Janssen Research & Development, LLC 2020-04-13
NCT03258502 Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV https://ClinicalTrials.gov/show/NCT03258502 Completed ReViral Ltd 2017-10-31
NCT03227029 Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT03227029 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2019-12-19
NCT03171142 Effect of Heliox on RSV Bronchiolitis https://ClinicalTrials.gov/show/NCT03171142 Completed Mansoura University Children Hospital 2016-08-01
NCT03102034 Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT03102034 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-05-25
NCT03099291 Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT03099291 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-04-30
NCT03062917 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis https://ClinicalTrials.gov/show/NCT03062917 Completed Imperial College Healthcare NHS Trust 2018-06-30
NCT02956837 A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women https://ClinicalTrials.gov/show/NCT02956837 Completed GlaxoSmithKline 2017-08-30
NCT02952339 Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT02952339 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-07-31
NCT02927873 RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months https://ClinicalTrials.gov/show/NCT02927873 Active, not recruiting GlaxoSmithKline 2019-02-19
NCT02878330 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. https://ClinicalTrials.gov/show/NCT02878330 Completed MedImmune LLC 2018-07-17
NCT02794870 Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT02794870 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-07-07
NCT02755948 A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers https://ClinicalTrials.gov/show/NCT02755948 Recruiting Imperial College London 2020-09-30
NCT02753413 Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women https://ClinicalTrials.gov/show/NCT02753413 Completed GlaxoSmithKline 2016-06-28
NCT02673476 A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT02673476 Completed Alios Biopharma Inc. 2016-10-31
NCT02654171 Viral Inhibition in Children for Treatment of RSV https://ClinicalTrials.gov/show/NCT02654171 Completed Ark Biosciences Inc. 2019-03-31
NCT02624947 A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization https://ClinicalTrials.gov/show/NCT02624947 Completed Novavax 2019-03-31
NCT02601612 Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT02601612 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-04-26
NCT03387137 Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT03387137 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2019-11-22
NCT02478333 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants https://ClinicalTrials.gov/show/NCT02478333 Completed Janssen Pharmaceutical K.K. 2015-07-31
NCT02419391 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine https://ClinicalTrials.gov/show/NCT02419391 Completed Bavarian Nordic 2015-12-31
NCT02387606 Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. https://ClinicalTrials.gov/show/NCT02387606 Completed Janssen Sciences Ireland UC 2015-09-21
NCT02360475 Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals’ Investigational RSV Vaccine (GSK3003891A), in Healthy Women https://ClinicalTrials.gov/show/NCT02360475 Completed GlaxoSmithKline 2015-07-02
NCT02325791 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants https://ClinicalTrials.gov/show/NCT02325791 Completed Regeneron Pharmaceuticals 2017-07-05
NCT02309320 A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171 https://ClinicalTrials.gov/show/NCT02309320 Completed Ablynx 2016-02-29
NCT02297594 Safety, Tolerability and PK Study of AK0529 in Healthy Human https://ClinicalTrials.gov/show/NCT02297594 Completed Ark Biosciences Inc. 2015-06-30
NCT02254421 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract https://ClinicalTrials.gov/show/NCT02254421 Completed Gilead Sciences 2017-04-17
NCT02247726 RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. https://ClinicalTrials.gov/show/NCT02247726 Completed Novavax 2016-07-31
NCT02237209 Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT02237209 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-04-30
NCT02231671 A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 https://ClinicalTrials.gov/show/NCT02231671 Completed Alios Biopharma Inc. 2014-09-30
NCT02202356 A Study of ALS-008176 in Infants Hospitalized With RSV https://ClinicalTrials.gov/show/NCT02202356 Completed Alios Biopharma Inc. 2018-02-15
NCT02201303 Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression https://ClinicalTrials.gov/show/NCT02201303 Completed GlaxoSmithKline 2015-07-02
NCT03384823 A Study of EDP-938 in Healthy Subjects https://ClinicalTrials.gov/show/NCT03384823 Completed Enanta Pharmaceuticals 2018-07-03
NCT02135614 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection https://ClinicalTrials.gov/show/NCT02135614 Completed Gilead Sciences 2017-03-27
NCT02114268 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults https://ClinicalTrials.gov/show/NCT02114268 Completed MedImmune LLC 2015-06-30
NCT02094365 A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model https://ClinicalTrials.gov/show/NCT02094365 Completed Alios Biopharma Inc. 2014-06-30
NCT01290419 Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine https://ClinicalTrials.gov/show/NCT01290419 Completed Novavax 2011-12-31
NCT02040831 Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT02040831 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-04-30
NCT03959488 A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children https://ClinicalTrials.gov/show/NCT03959488 Recruiting MedImmune LLC 2022-12-02
NCT01960686 RSV F Dose-Ranging Study in Women https://ClinicalTrials.gov/show/NCT01960686 Completed Novavax 2014-04-30
NCT01909843 ALX-0171 Safety Study in Adults With Hyperresponsive Airways https://ClinicalTrials.gov/show/NCT01909843 Completed Ablynx 2013-12-31
NCT01906164 Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01906164 Completed Alios Biopharma Inc. 2013-11-30
NCT01905215 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccines https://ClinicalTrials.gov/show/NCT01905215 Completed GlaxoSmithKline 2014-04-09
NCT01893554 Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children https://ClinicalTrials.gov/show/NCT01893554 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-12-31
NCT01875926 ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT01875926 Completed Ablynx 2013-10-31
NCT01852266 Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT01852266 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-07-31
NCT01805921 RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. https://ClinicalTrials.gov/show/NCT01805921 Completed ReiThera Srl 2015-08-31
NCT01801293 A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 https://ClinicalTrials.gov/show/NCT01801293 Completed Gilead Sciences 2013-04-30
NCT01756482 Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) https://ClinicalTrials.gov/show/NCT01756482 Completed Gilead Sciences 2013-06-30
NCT01502072 Respiratory Syncytial Virus - RSV Protocol https://ClinicalTrials.gov/show/NCT01502072 Completed M.D. Anderson Cancer Center 2020-02-01
NCT01483911 ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT01483911 Completed Ablynx 2012-05-31
NCT01466062 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions https://ClinicalTrials.gov/show/NCT01466062 Completed AbbVie 2012-04-30
NCT01459198 Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT01459198 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-06-30
NCT01355016 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01355016 Completed MicroDose Therapeutx, Inc 2011-11-30
NCT01349543 The Development of a Human Model of Respiratory Syncytial Virus Infection https://ClinicalTrials.gov/show/NCT01349543 Completed Imperial College London 2013-10-31
NCT04267822 Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV https://ClinicalTrials.gov/show/NCT04267822 Recruiting ReViral Ltd 2022-06-30
NCT04227210 Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults https://ClinicalTrials.gov/show/NCT04227210 Active, not recruiting Meissa Vaccines, Inc. 2020-07-31
NCT04126213 Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants https://ClinicalTrials.gov/show/NCT04126213 Active, not recruiting GlaxoSmithKline 2020-07-07
NCT04090658 A Study to Test GlaxoSmithKline’s (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine’s Safety and Immune Response in Japanese Older Adults https://ClinicalTrials.gov/show/NCT04090658 Active, not recruiting GlaxoSmithKline 2020-01-10
NCT04065698 Pharmacokinetics and Safety of RV521 Formulations https://ClinicalTrials.gov/show/NCT04065698 Completed ReViral Ltd 2019-09-02
NCT04056611 Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) https://ClinicalTrials.gov/show/NCT04056611 Recruiting Janssen Sciences Ireland UC 2022-08-15
NCT03979313 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants https://ClinicalTrials.gov/show/NCT03979313 Recruiting MedImmune LLC 2022-05-02
NCT03919591 RSV Study in Adults 60 to 75 Years of Age https://ClinicalTrials.gov/show/NCT03919591 Completed Hvivo 2019-07-11
NCT03814590 A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults https://ClinicalTrials.gov/show/NCT03814590 Active, not recruiting GlaxoSmithKline 2019-12-12
NCT03782662 Drug Interaction Study With RV521 in Healthy Volunteer Subjects https://ClinicalTrials.gov/show/NCT03782662 Completed ReViral Ltd 2019-03-17
NCT03755778 Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects https://ClinicalTrials.gov/show/NCT03755778 Completed Enanta Pharmaceuticals 2019-01-21
NCT03750383 Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT03750383 Completed Enanta Pharmaceuticals 2018-11-17
NCT03728413 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT03728413 Recruiting Imperial College London 2023-09-28
NCT03699202 Anti-RSV Study in Chinese Patients (ASCENT) https://ClinicalTrials.gov/show/NCT03699202 Recruiting Ark Biosciences Inc. 2020-01-31
NCT03691623 A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model https://ClinicalTrials.gov/show/NCT03691623 Completed Enanta Pharmaceuticals 2019-09-30
NCT03674177 A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women https://ClinicalTrials.gov/show/NCT03674177 Completed GlaxoSmithKline 2019-04-16
NCT03636906 Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV https://ClinicalTrials.gov/show/NCT03636906 Active, not recruiting GlaxoSmithKline 2020-01-16
NCT03629145 Music Therapy With Intubated and Sedated Pediatric Patients https://ClinicalTrials.gov/show/NCT03629145 Completed Children’s Healthcare of Atlanta 2019-03-01
NCT03624790 Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT03624790 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-12-31
NCT03614676 A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance https://ClinicalTrials.gov/show/NCT03614676 Active, not recruiting GlaxoSmithKline 2021-08-04
NCT03596801 Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT03596801 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-04-30
NCT03473002 A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT03473002 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2019-02-14
NCT03422237 Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age https://ClinicalTrials.gov/show/NCT03422237 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-09-20
NCT01230645 RV568 - Viral Challenge With RSV https://ClinicalTrials.gov/show/NCT01230645 Completed Respivert Ltd 2010-12-31
NCT01065935 Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) https://ClinicalTrials.gov/show/NCT01065935 Completed Alnylam Pharmaceuticals 2012-04-30
NCT01006629 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children https://ClinicalTrials.gov/show/NCT01006629 Completed Abbott 2010-04-30
NCT04444284 Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children https://ClinicalTrials.gov/show/NCT04444284 Recruiting Meissa Vaccines, Inc. 2021-03-31
NCT02873286 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults https://ClinicalTrials.gov/show/NCT02873286 Completed Bavarian Nordic 2018-12-31
NCT04138056 A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses to Healthy Non-Pregnant Women https://ClinicalTrials.gov/show/NCT04138056 Active, not recruiting GlaxoSmithKline 2020-02-25
NCT00658086 Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) https://ClinicalTrials.gov/show/NCT00658086 Completed Alnylam Pharmaceuticals 2009-04-30
NCT00504907 Safety Study of Oral BTA9881 to Treat RSV Infection https://ClinicalTrials.gov/show/NCT00504907 Completed Vaxart 2008-12-31
NCT00496821 Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT00496821 Completed Alnylam Pharmaceuticals NA
NCT00493285 Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age https://ClinicalTrials.gov/show/NCT00493285 Completed MedImmune LLC 2009-11-30
NCT00435994 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections https://ClinicalTrials.gov/show/NCT00435994 Completed Indiana University 2009-03-31
NCT00316264 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season https://ClinicalTrials.gov/show/NCT00316264 Completed MedImmune LLC 2007-02-28
NCT00232635 A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT https://ClinicalTrials.gov/show/NCT00232635 Completed Arrow Therapeutics 2006-07-31
NCT00192504 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection https://ClinicalTrials.gov/show/NCT00192504 Completed MedImmune LLC NA
NCT00192478 Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 https://ClinicalTrials.gov/show/NCT00192478 Completed MedImmune LLC 2006-05-31
NCT00192465 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults https://ClinicalTrials.gov/show/NCT00192465 Completed MedImmune LLC 2004-04-30
NCT01968083 Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children https://ClinicalTrials.gov/show/NCT01968083 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-05-31
NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children https://ClinicalTrials.gov/show/NCT00129766 Completed MedImmune LLC 2006-05-31
NCT00001903 Prevention of RSV Infections in Bone Marrow Transplant Recipients https://ClinicalTrials.gov/show/NCT00001903 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02984280 Specific Respiratory Infections as Triggers of Acute Medical Events https://ClinicalTrials.gov/show/NCT02984280 Completed University College, London 2017-03-31
NCT02786381 Idylla IFV-RSV Panel Clinical Testing https://ClinicalTrials.gov/show/NCT02786381 Completed Janssen Pharmaceutica N.V., Belgium 2016-10-31
NCT01302418 Collection and Testing of Respiratory Samples https://ClinicalTrials.gov/show/NCT01302418 Completed QIAGEN Gaithersburg, Inc 2011-07-31
NCT01297504 A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America https://ClinicalTrials.gov/show/NCT01297504 Completed AbbVie 2013-08-31
NCT02016690 Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis® https://ClinicalTrials.gov/show/NCT02016690 Completed AbbVie 2015-12-31
NCT01915394 Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) https://ClinicalTrials.gov/show/NCT01915394 Completed Ankara University 2014-05-31
NCT01754428 Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age https://ClinicalTrials.gov/show/NCT01754428 Completed Gilead Sciences 2013-05-31
NCT01537198 Surveillance of Synagis in Korean Pediatric Patients https://ClinicalTrials.gov/show/NCT01537198 Completed AbbVie 2014-06-30
NCT04431050 Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens https://ClinicalTrials.gov/show/NCT04431050 Recruiting Imperial College London 2021-04-30
NCT03909867 Emission Patterns of Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT03909867 Active, not recruiting Wake Forest University Health Sciences 2021-04-30
NCT03757429 Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus https://ClinicalTrials.gov/show/NCT03757429 Recruiting Uppsala University 2020-05-31
NCT03698084 RESCEU: Defining the Burden of RSV Disease https://ClinicalTrials.gov/show/NCT03698084 Recruiting University of Oxford 2020-08-31
NCT03627572 RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants https://ClinicalTrials.gov/show/NCT03627572 Recruiting UMC Utrecht 2020-12-31
NCT03621930 RESCEU Study, Defining the Burden of Disease of RSV in Older Adults https://ClinicalTrials.gov/show/NCT03621930 Active, not recruiting UMC Utrecht 2019-12-01
NCT01107535 Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection https://ClinicalTrials.gov/show/NCT01107535 Completed Abbott 2011-02-28
NCT01090557 Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study https://ClinicalTrials.gov/show/NCT01090557 Completed Winthrop University Hospital 2009-10-31
NCT01075178 Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease https://ClinicalTrials.gov/show/NCT01075178 Completed Abbott 2010-01-31
NCT01922648 RSV Observational Study 2 https://ClinicalTrials.gov/show/NCT01922648 Completed University of Oxford 2015-04-30
NCT00609635 Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly https://ClinicalTrials.gov/show/NCT00609635 Completed West Penn Allegheny Health System 2009-04-30
NCT00593918 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children https://ClinicalTrials.gov/show/NCT00593918 Completed University of Wisconsin, Madison 2008-05-31
NCT00585481 Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children https://ClinicalTrials.gov/show/NCT00585481 Completed Abbott 2010-12-31
NCT00420966 Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy https://ClinicalTrials.gov/show/NCT00420966 Completed Sunnybrook Health Sciences Centre 2017-06-26
NCT00384462 Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants https://ClinicalTrials.gov/show/NCT00384462 Completed MedImmune LLC 2007-11-30
NCT00111878 Study to Evaluate MEDI-534 in Healthy Adults https://ClinicalTrials.gov/show/NCT00111878 Completed MedImmune LLC NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01155193 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany https://ClinicalTrials.gov/show/NCT01155193 Completed AbbVie 2016-07-31